A detailed history of Black Rock Inc. transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Black Rock Inc. holds 1,129,143 shares of VRCA stock, worth $8.98 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,129,143
Previous 1,114,060 1.35%
Holding current value
$8.98 Million
Previous $6.6 Million 24.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$5.89 - $9.56 $88,838 - $144,193
15,083 Added 1.35%
1,129,143 $8.23 Million
Q1 2024

May 10, 2024

SELL
$4.74 - $6.81 $102,777 - $147,661
-21,683 Reduced 1.91%
1,114,060 $6.6 Million
Q4 2023

Feb 13, 2024

BUY
$2.93 - $7.32 $248,150 - $619,952
84,693 Added 8.06%
1,135,743 $8.31 Million
Q3 2023

Nov 13, 2023

BUY
$3.75 - $7.46 $178,762 - $355,618
47,670 Added 4.75%
1,051,050 $4.08 Million
Q2 2023

Aug 11, 2023

BUY
$5.32 - $6.79 $4.77 Million - $6.09 Million
896,712 Added 840.66%
1,003,380 $5.79 Million
Q1 2023

May 12, 2023

BUY
$2.88 - $8.51 $62,809 - $185,594
21,809 Added 25.7%
106,668 $693,000
Q4 2022

Feb 13, 2023

SELL
$2.09 - $3.39 $406,373 - $659,141
-194,437 Reduced 69.62%
84,859 $233,000
Q3 2022

Nov 14, 2022

BUY
$2.17 - $4.3 $146,750 - $290,796
67,627 Added 31.95%
279,296 $816,000
Q2 2022

Aug 12, 2022

SELL
$1.81 - $8.93 $1.03 Million - $5.07 Million
-568,151 Reduced 72.86%
211,669 $407,000
Q1 2022

May 12, 2022

SELL
$7.59 - $9.49 $111,163 - $138,990
-14,646 Reduced 1.84%
779,820 $6.32 Million
Q4 2021

Feb 10, 2022

BUY
$9.1 - $13.36 $1.36 Million - $1.99 Million
149,248 Added 23.13%
794,466 $7.28 Million
Q3 2021

Nov 09, 2021

SELL
$9.55 - $13.96 $550,318 - $804,445
-57,625 Reduced 8.2%
645,218 $8.07 Million
Q2 2021

Aug 11, 2021

BUY
$9.77 - $15.33 $6.87 Million - $10.8 Million
702,843 New
702,843 $7.94 Million

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.